{"id":"NCT02234115","sponsor":"Foresee Pharmaceuticals Co., Ltd.","briefTitle":"Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate in Subjects With Advanced Prostate Carcinoma","officialTitle":"An Open-Labeled, Singled-Arm Study of the Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate for Injectable Suspension (LMIS 50 mg) in Subjects With Advanced Prostate Carcinoma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-08","primaryCompletion":"2016-08-30","completion":"2017-01-05","firstPosted":"2014-09-09","resultsPosted":"2018-04-13","lastUpdate":"2019-03-05"},"enrollment":137,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Prostatic Neoplasms"],"interventions":[{"type":"DRUG","name":"Leuprolide Mesylate","otherNames":[]}],"arms":[{"label":"Leuprolide Mesylate 50mg","type":"EXPERIMENTAL"}],"summary":"The study will evaluate if Leuprolide Mesylate is safe and effective in the treatment of subjects with advanced prostate carcinoma, when administered as two injections six months apart.","primaryOutcome":{"measure":"Efficacy of Leuprolide Mesylate (LMIS 50mg)","timeFrame":"baseline to 28 days, 28 days to 336 days","effectByArm":[{"arm":"Leuprolide Mesylate 50mg","deltaMin":97,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":19},"locations":{"siteCount":29,"countries":["United States","Austria","Czechia","Germany","Lithuania","Poland","Slovakia","Taiwan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":20,"n":137},"commonTop":["Hot flush","Hypertension","Pain in extremity","Injection site pain","Fatigue"]}}